Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a research note published on Friday morning,Benzinga reports.

Xenetic Biosciences Trading Up 2.3 %

Shares of NASDAQ:XBIO opened at $4.11 on Friday. The business has a 50-day moving average price of $3.90 and a 200 day moving average price of $3.92. The company has a market capitalization of $6.33 million, a price-to-earnings ratio of -1.47 and a beta of 2.25. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The business had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.75 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. As a group, equities research analysts predict that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.